In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.
Advertisement

Related Content

Earnings Updates, In Brief: Momenta, Acorda, Sangamo, Lundbeck, Actelion, Alnylam, Seattle Genetics
Acorda Positions Ampyra For Large Market Of Post-Stroke Deficits
Ampyra Trial Failure Is Not All Bad News For Acorda
Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need
Behind The Approval Letter: A Year Of Drug Review Profiles
Ampyra Approval: Acorda's Lessons Learned
Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses
Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses
FDA's Temple Discusses Measuring Efficacy When Mean Effect Is Limited
Acorda's Risks With Fampridine Development Look Likely To Pay Off

Topics

Advertisement
UsernamePublicRestriction

Register

PS004628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel